Neurodevelopmental predictors of treatment response in schizophrenia and bipolar disorder.

age at onset of disease bipolar disorder neurodevelopment neurological soft signs schizophrenia treatment response

Journal

Psychological medicine
ISSN: 1469-8978
Titre abrégé: Psychol Med
Pays: England
ID NLM: 1254142

Informations de publication

Date de publication:
15 Oct 2024
Historique:
medline: 15 10 2024
pubmed: 15 10 2024
entrez: 15 10 2024
Statut: aheadofprint

Résumé

Treatment resistance is a major challenge in psychiatric disorders. Early detection of potential future resistance would improve prognosis by reducing the delay to appropriate treatment adjustment and recovery. Here, we sought to determine whether neurodevelopmental markers can predict therapeutic response. Healthy controls ( Developmental abnormalities were more frequent in schizophrenia and bipolar disorder than in controls. NSS significantly differed between controls, responsive, and resistant participants with schizophrenia (5.5 ± 3.0, 7.0 ± 4.0, 15.0 ± 6.0 respectively, Neurodevelopmental features such as NSS and age of clinical onset provide a means to identify patients who may require rapid treatment adaptation.

Sections du résumé

BACKGROUND BACKGROUND
Treatment resistance is a major challenge in psychiatric disorders. Early detection of potential future resistance would improve prognosis by reducing the delay to appropriate treatment adjustment and recovery. Here, we sought to determine whether neurodevelopmental markers can predict therapeutic response.
METHODS METHODS
Healthy controls (
RESULTS RESULTS
Developmental abnormalities were more frequent in schizophrenia and bipolar disorder than in controls. NSS significantly differed between controls, responsive, and resistant participants with schizophrenia (5.5 ± 3.0, 7.0 ± 4.0, 15.0 ± 6.0 respectively,
CONCLUSIONS CONCLUSIONS
Neurodevelopmental features such as NSS and age of clinical onset provide a means to identify patients who may require rapid treatment adaptation.

Identifiants

pubmed: 39402801
doi: 10.1017/S0033291724001776
pii: S0033291724001776
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-12

Subventions

Organisme : Agence Nationale de la Recherche
ID : ANR-19-CHIA-0010-01 "Big2Small"
Organisme : HORIZON EUROPE Framework Programme
ID : H2020-SC1-2017, 754907

Auteurs

Anton Iftimovici (A)

Université Paris Cité, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, Paris, France.
Institut de Psychiatrie, CNRS GDR 3557, Paris, France.
GHU Paris Psychiatrie et Neurosciences, Paris, France.
NeuroSpin, Atomic Energy Commission, Gif-sur Yvette, France.

Emma Krebs (E)

Université Paris Cité, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, Paris, France.

William Dalfin (W)

Université Paris Cité, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, Paris, France.

Adrien Legrand (A)

GHU Paris Psychiatrie et Neurosciences, Paris, France.

Linda Scoriels (L)

Université Paris Cité, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, Paris, France.
Institut de Psychiatrie, CNRS GDR 3557, Paris, France.

Gilles Martinez (G)

GHU Paris Psychiatrie et Neurosciences, Paris, France.

Narjes Bendjemaa (N)

GHU Paris Psychiatrie et Neurosciences, Paris, France.

Edouard Duchesnay (E)

NeuroSpin, Atomic Energy Commission, Gif-sur Yvette, France.

Boris Chaumette (B)

Université Paris Cité, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, Paris, France.
Institut de Psychiatrie, CNRS GDR 3557, Paris, France.
GHU Paris Psychiatrie et Neurosciences, Paris, France.
Department of Psychiatry, McGill University, Montréal, Québec, Canada.

Marie-Odile Krebs (MO)

Université Paris Cité, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, Paris, France.
Institut de Psychiatrie, CNRS GDR 3557, Paris, France.
GHU Paris Psychiatrie et Neurosciences, Paris, France.

Classifications MeSH